Dr. Hönle AG
Dr. Hönle AG (0O27.L) Financial Performance & Income Statement Overview
Analyze Dr. Hönle AG (0O27.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Dr. Hönle AG (0O27.L) Income Statement & Financial Overview
Explore comprehensive income reports for Dr. Hönle AG 0O27.L, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $25.76M | $21.41M | $26.67M | $23.95M |
| Cost of Revenue | $10.24M | $7.51M | $12.79M | $9.12M |
| Gross Profit | $15.52M | $13.90M | $13.89M | $14.83M |
| Gross Profit Ratio | $0.60 | $0.65 | $0.52 | $0.62 |
| R&D Expenses | $0.00 | $0.00 | $7.29M | $0.00 |
| SG&A Expenses | $3.47M | $3.17M | $4.26M | $4.04M |
| Operating Expenses | $14.88M | $14.26M | $24.03M | $14.85M |
| Total Costs & Expenses | $25.13M | $21.77M | $36.82M | $23.95M |
| Interest Income | $3000.00 | $82000.00 | $32000.00 | $9000.00 |
| Interest Expense | $476000.00 | $507000.00 | $583000.00 | $502000.00 |
| Depreciation & Amortization | $1.37M | $1.38M | $9.09M | $1.38M |
| EBITDA | $2.001M | $1.11M | -$1.03M | $1.39M |
| EBITDA Ratio | $0.08 | $0.05 | -$0.04 | $0.06 |
| Operating Income | $631000.00 | -$357000.00 | -$10.14M | -$5000.00 |
| Operating Income Ratio | $0.02 | -$0.02 | -$0.38 | -$0.00 |
| Other Income/Expenses (Net) | -$473000.00 | -$425000.00 | -$558000.00 | -$492000.00 |
| Income Before Tax | $158000.00 | -$782000.00 | -$10.70M | -$497000.00 |
| Income Before Tax Ratio | $0.006 | -$0.04 | -$0.40 | -$0.02 |
| Income Tax Expense | -$21000.00 | -$204000.00 | $1.35M | -$248000.00 |
| Net Income | $194000.00 | -$592000.00 | -$12.29M | -$265000.00 |
| Net Income Ratio | $0.008 | -$0.03 | -$0.46 | -$0.01 |
| EPS | $0.03 | -$0.10 | -$2.03 | -$0.04 |
| Diluted EPS | $0.03 | -$0.10 | -$2.03 | -$0.04 |
| Weighted Avg Shares Outstanding | $6.06M | $6.06M | $6.06M | $6.06M |
| Weighted Avg Shares Outstanding (Diluted) | $6.06M | $6.06M | $6.06M | $6.06M |
Over the last four quarters, Dr. Hönle AG's revenue moved from $23.95M in Q3 2024 to $25.76M in Q2 2025. Operating income in Q2 2025 was $631000.00, with a strong operating margin of 2%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Dr. Hönle AG remained robust at $2.001M, reflecting operational efficiency. Net income rose to $194000.00, with an EPS of $0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan